Canada Markets open in 8 hrs 57 mins

GB Sciences, Inc. (GBLX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0375+0.0010 (+2.74%)
At close: 02:32PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.0365
Open0.0380
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0340 - 0.0380
52 Week Range0.0200 - 0.1300
Volume929,091
Avg. Volume410,431
Market Cap11.904M
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-0.0070
Earnings DateAug. 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

    The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies Gb Sciences Gb Sciences LAS VEGAS, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. "This is a landmark event for Gb Sciences," said Chairman

  • GlobeNewswire

    Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

    Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies Gb Sciences, Inc Gb Sciences, Inc LAS VEGAS, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine release syndrome (CRS), one of the most dangerous complications of COVID-19. With reports of the arrival of the Omicron

  • GlobeNewswire

    Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships

    Biopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships Gb Sciences Gb Sciences LAS VEGAS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed